Abstract
LHRHa suppresses gonadarche in girls with CPP, but little information is available regarding the response of males to this therapy. Four boys with CPP received LHRHa for 12 consecutive months. Prior to therapy, the patients had Tanner stage II-IV pubertal development, a mean testicular volume of 16±3 (SE) ml, a chronologic age of 7.7±0.6 years and a bone age of 12.9±0.4 years. Following therapy, 3/4 boys demonstrated regression of secondary sex characteristics and all had a marked decrease in testicular size to 7±1 ml. Bone age advanced 4.5±0.5 months during 12 months of exposure to LHRHa. The pretreatment pubertal growth velocity of 13.5±2.7 cm/yr fell significantly to 5.5±.13 cm/yr over the year of therapy. Predicted height was increased to 3.84±2.24 cm. Endocrinologic parameters are summarized below:
1=plasma testosterone (ng%) in a PM pool; 2=mean of 8h pulsation study (mIU/ml LER 907); 3=ΔFSH or ΔLH after LHRH (2.5 mcg/kg sc).
In boys with CPP, LHRHa is capable of: 1) reversing the clinical features of precocity, 2) abolishing the pulsatile release of gonadotropins with subsequent suppression of testosterone production, and 3) retarding skeletal maturation, slowing growth velocity, and improving predicted adult stature.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Beardsworth, D., Wierman, M., Mansfield, J. et al. USE OF AN LHRH AGONIST (LHRHa) IN THE TREATMENT OF MALES WITH CENTRAL PRECOCIOUS PUBERTY (CPP). Pediatr Res 18 (Suppl 4), 164 (1984). https://doi.org/10.1203/00006450-198404001-00425
Issue Date:
DOI: https://doi.org/10.1203/00006450-198404001-00425